Sermorelin and GHRH(1-29): What the Growth-Hormone-Releasing Hormone Literature Reports

A research overview of GHRH and its 1-29 fragment sermorelin: discovery from pancreatic tumours, the minimal active core, plasma degradation at position 2, receptor cloning and analogue stabilization.

Share

Sermorelin is the laboratory name for GHRH(1-29) amide, the first twenty-nine residues of human growth-hormone-releasing hormone. It is one of the more instructive peptides in the endocrine literature, because almost every question a peptide chemist cares about — where a sequence came from, how much of it is actually needed, why it disappears so quickly in plasma, what receptor it acts on, and how analogue design changes its behaviour — has a well-documented answer in the published record. This article summarises that record as laboratory and pharmacology research. It is not a guide to use in people, and no dosing information is given.

A hormone found in the wrong organ

GHRH was predicted long before it was isolated. Physiologists had inferred for years that the hypothalamus must release a factor that drives growth hormone secretion from the anterior pituitary, but hypothalamic tissue yields vanishingly small amounts of peptide, and the purification repeatedly stalled.

The breakthrough came from pathology rather than from the hypothalamus. Certain pancreatic islet tumours were associated with acromegaly, and the tumours themselves turned out to be secreting a growth-hormone-releasing factor in gram-scale abundance compared with brain tissue. In 1982 two groups reported the characterisation of this material within weeks of each other. Guillemin and colleagues described a growth hormone-releasing factor purified from a human pancreatic tumour that had caused acromegaly (Science, 1982), and Rivier, Spiess, Thorner and Vale reported the characterisation of a releasing factor from a human pancreatic islet tumour (Nature, 1982). The sequences obtained from these ectopic sources matched the hypothalamic hormone, and the peptide became known as GHRH (also written GRF in the older literature).

The full-length human peptide is 44 residues, usually written GHRH(1-44)-NH2, and it belongs to the glucagon/secretin/VIP structural family.

Why the 1-29 fragment became the working molecule

Once synthetic GRF was available, structure–activity work moved quickly. Groups systematically truncated and substituted the sequence to map which parts of the molecule the pituitary actually reads. Ling and colleagues, for example, published syntheses and in vitro bioactivity data for human growth hormone-releasing factor analogues substituted at position 1 (Biochemical and Biophysical Research Communications, 1984), part of a broader programme of analogue and fragment chemistry on GRF that included C-terminal truncation.

The conclusion from that work was that the C-terminal residues beyond position 29 are largely dispensable for receptor activation in vitro: GRF(1-29)-NH2 retains the biological activity of the full-length hormone in these assays. That fragment, amidated at the C-terminus, is sermorelin. It is shorter, cheaper to synthesise, and easier to purify than GHRH(1-44), which is why it became the standard research form of the native agonist.

The complementary finding is that the N-terminus is not dispensable at all. Modifications at position 1 and the immediate N-terminal region change activity sharply, which is consistent with the N-terminal segment of GHRH being the business end of the molecule for receptor engagement.

The position-2 problem: why GHRH is so short-lived

The same N-terminus that makes GHRH active also makes it fragile. Frohman and colleagues examined what happens to GHRH in plasma and reported rapid enzymatic degradation both in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus (Journal of Clinical Investigation, 1986). The dominant cleavage removes the first two residues, Tyr-Ala, generating GHRH(3-44) — a truncated species that no longer activates the receptor.

That cleavage is the signature of dipeptidyl peptidase IV (DPP-IV), a serine peptidase that trims X-Ala or X-Pro dipeptides from peptide N-termini and which acts on several members of the glucagon/secretin family. The practical consequence reported in the literature is a very short circulating half-life for native GHRH and for GHRH(1-29), measured in minutes.

For anyone handling these peptides in the laboratory, the same chemistry is a handling note rather than a clinical one: serum-containing media and plasma samples are degradation environments, and analytical work on GHRH fragments has to account for the (3-29)/(3-44) truncation product appearing alongside the parent.

The receptor

The target of GHRH was cloned a decade after the hormone was sequenced. Mayo reported the molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone (Molecular Endocrinology, 1992), and Gaylinn and colleagues reported the cloning and expression of the human anterior pituitary receptor the following year (Molecular Endocrinology, 1993).

The GHRH receptor is a class B (secretin-family) G-protein-coupled receptor, expressed in the anterior pituitary, and it signals principally through Gs and cyclic AMP. Having a cloned receptor turned GHRH pharmacology into a tractable in vitro problem: binding and cAMP-accumulation assays in cells expressing the recombinant receptor became the standard way to rank analogues, rather than whole-animal or pituitary-cell preparations alone.

It is worth distinguishing this receptor from the growth hormone secretagogue receptor (GHS-R1a), the target of the ghrelin-mimetic peptides such as GHRP-6, hexarelin and ipamorelin. These are two separate receptors and two separate literatures, which is why GHRH analogues and GHRP-class peptides are studied as distinct classes.

Stabilizing the molecule: analogue research

Because degradation at position 2 is the main route of inactivation, analogue chemistry on GHRH has concentrated on blocking or bypassing it. Two general strategies appear in the literature: substituting the vulnerable residues (for example D-amino acid or alkylated residues at positions 1 and 2) so DPP-IV cannot cleave, and attaching the peptide to a long-lived carrier so that the circulating pool is replenished.

CJC-1295 is the most cited example of the second strategy combined with the first. It is a GHRH(1-29) analogue carrying stabilizing substitutions and a reactive linker designed to form a covalent bond with serum albumin, so that the albumin pool acts as a depot. Teichman and colleagues reported prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults (Journal of Clinical Endocrinology & Metabolism, 2006), describing sustained elevations of measured GH and IGF-I relative to baseline after administration. That study is reported here only as published evidence that half-life extension of a GHRH(1-29) backbone changes its pharmacokinetic and secretory profile; it is not a statement about outcomes or suitability for any use.

The contrast between sermorelin and the stabilized analogues is the point of interest for researchers: the same 29-residue core, with and without protection at the DPP-IV site, behaves very differently in a biological matrix.

What this means for laboratory work

A few practical observations follow from the published record. Sermorelin is an amidated 29-residue peptide, so identity testing should confirm the C-terminal amide (a 1 Da difference from the free acid) as well as the total mass. Degradation to the des-Tyr-Ala species is the expected failure mode in serum-containing systems and should be looked for explicitly by mass spectrometry. And because GHRH-family peptides and GHS-R ligands act at different receptors, assay systems have to be chosen to match the class being tested.

Summary

GHRH was isolated in 1982 from ectopic pancreatic tumours rather than from the hypothalamus, structure–activity work established GHRH(1-29)-NH2 (sermorelin) as the minimal fragment retaining in vitro activity, plasma studies identified N-terminal cleavage at position 2 as the route of inactivation, the pituitary receptor was cloned in 1992–1993, and later analogue research such as CJC-1295 addressed the degradation problem directly. The whole sequence of findings is a compact case study in how a native peptide becomes a research tool.

References

  • Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-587. doi:10.1126/science.6812220.
  • Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982;300(5889):276-278. doi:10.1038/300276a0.
  • Ling N, Baird A, Wehrenberg WB, Ueno N, Munegumi T, Chiang TC, et al. Synthesis and in vitro bioactivity of human growth hormone-releasing factor analogs substituted at position-1. Biochemical and Biophysical Research Communications. 1984;122(1):304-310. doi:10.1016/0006-291x(84)90475-3.
  • Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. Journal of Clinical Investigation. 1986;78(4):906-913. doi:10.1172/JCI112679.
  • Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Molecular Endocrinology. 1992;6(10):1734-1744. doi:10.1210/mend.6.10.1333056.
  • Gaylinn BD, Harrison JK, Zysk JR, Lyons CE, Lynch KR, Thorner MO. Molecular cloning and expression of a human anterior pituitary receptor for growth hormone-releasing hormone. Molecular Endocrinology. 1993;7(1):77-84. doi:10.1210/mend.7.1.7680413.
  • Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536.

Research use only. All products sold by Morpheus Research are intended strictly for laboratory research and are not for human or veterinary consumption. Nothing in this article is medical advice, and no statement here is intended to diagnose, treat, cure or prevent any condition. Study findings are reported as published and should not be read as evidence of effects in people.